Cargando…
Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice
AIM: To assess gender differences in ankylosing spondylitis (AS) patients in relation to tumor necrosis factor alpha inhibitor (TNFi) drug survival and occurrence of adverse events in daily practice in a large peripheral hospital. METHOD: Retrospective data were collected from AS patients treated wi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901415/ https://www.ncbi.nlm.nih.gov/pubmed/29611349 http://dx.doi.org/10.1111/1756-185X.13271 |
_version_ | 1783314612010090496 |
---|---|
author | Rusman, Tamara ten Wolde, Saskia Euser, Sjoerd M. van der Ploeg, Tjeerd van Hall, Odile van der Horst‐Bruinsma, Irene E. |
author_facet | Rusman, Tamara ten Wolde, Saskia Euser, Sjoerd M. van der Ploeg, Tjeerd van Hall, Odile van der Horst‐Bruinsma, Irene E. |
author_sort | Rusman, Tamara |
collection | PubMed |
description | AIM: To assess gender differences in ankylosing spondylitis (AS) patients in relation to tumor necrosis factor alpha inhibitor (TNFi) drug survival and occurrence of adverse events in daily practice in a large peripheral hospital. METHOD: Retrospective data were collected from AS patients treated with etanercept, infliximab and adalimumab between January 2004 and January 2014. Kaplan–Meier survival curves were conducted to describe the drug survival and occurrence of adverse events in time. RESULTS: Overall, 122 AS patients (60.7% male) were included over a 10‐year time period, with a mean treatment period of 51 months (1–127 months). In total, 21 (17.2%) patients stopped the TNFi, mainly due to inefficacy (52.4%). Female patients showed a significant shorter treatment period compared to males (33.4 vs. 44.9 months). In addition, female patients switched more between TNFi compared to males (26.9% vs. 16.3%) and had a significantly higher risk at developing infections compared to male patients (26% vs.19%). CONCLUSION: Females stayed on the same TNFi for a significantly shorter period compared to males (33.4 vs. 44.9 months) and the most important reason to stop or switch the drug was inefficacy. Moreover, females seemed to be more prone to infections during TNFi treatment than males. |
format | Online Article Text |
id | pubmed-5901415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59014152018-04-24 Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice Rusman, Tamara ten Wolde, Saskia Euser, Sjoerd M. van der Ploeg, Tjeerd van Hall, Odile van der Horst‐Bruinsma, Irene E. Int J Rheum Dis Original Articles AIM: To assess gender differences in ankylosing spondylitis (AS) patients in relation to tumor necrosis factor alpha inhibitor (TNFi) drug survival and occurrence of adverse events in daily practice in a large peripheral hospital. METHOD: Retrospective data were collected from AS patients treated with etanercept, infliximab and adalimumab between January 2004 and January 2014. Kaplan–Meier survival curves were conducted to describe the drug survival and occurrence of adverse events in time. RESULTS: Overall, 122 AS patients (60.7% male) were included over a 10‐year time period, with a mean treatment period of 51 months (1–127 months). In total, 21 (17.2%) patients stopped the TNFi, mainly due to inefficacy (52.4%). Female patients showed a significant shorter treatment period compared to males (33.4 vs. 44.9 months). In addition, female patients switched more between TNFi compared to males (26.9% vs. 16.3%) and had a significantly higher risk at developing infections compared to male patients (26% vs.19%). CONCLUSION: Females stayed on the same TNFi for a significantly shorter period compared to males (33.4 vs. 44.9 months) and the most important reason to stop or switch the drug was inefficacy. Moreover, females seemed to be more prone to infections during TNFi treatment than males. John Wiley and Sons Inc. 2018-04-02 2018-04 /pmc/articles/PMC5901415/ /pubmed/29611349 http://dx.doi.org/10.1111/1756-185X.13271 Text en © 2018 The Authors. International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Rusman, Tamara ten Wolde, Saskia Euser, Sjoerd M. van der Ploeg, Tjeerd van Hall, Odile van der Horst‐Bruinsma, Irene E. Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice |
title | Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice |
title_full | Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice |
title_fullStr | Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice |
title_full_unstemmed | Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice |
title_short | Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice |
title_sort | gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901415/ https://www.ncbi.nlm.nih.gov/pubmed/29611349 http://dx.doi.org/10.1111/1756-185X.13271 |
work_keys_str_mv | AT rusmantamara genderdifferencesinretentionrateoftumornecrosisfactoralphainhibitortreatmentinankylosingspondylitisaretrospectivecohortstudyindailypractice AT tenwoldesaskia genderdifferencesinretentionrateoftumornecrosisfactoralphainhibitortreatmentinankylosingspondylitisaretrospectivecohortstudyindailypractice AT eusersjoerdm genderdifferencesinretentionrateoftumornecrosisfactoralphainhibitortreatmentinankylosingspondylitisaretrospectivecohortstudyindailypractice AT vanderploegtjeerd genderdifferencesinretentionrateoftumornecrosisfactoralphainhibitortreatmentinankylosingspondylitisaretrospectivecohortstudyindailypractice AT vanhallodile genderdifferencesinretentionrateoftumornecrosisfactoralphainhibitortreatmentinankylosingspondylitisaretrospectivecohortstudyindailypractice AT vanderhorstbruinsmairenee genderdifferencesinretentionrateoftumornecrosisfactoralphainhibitortreatmentinankylosingspondylitisaretrospectivecohortstudyindailypractice |